Oncology Business Management | Specialty

Innovative Payment Models in Cancer Care

December 15th 2014

Faced with steep regulations, slashed reimbursement rates, and a shift in focus from fee-for-service (FFS) to delivering value, insurers and physician groups are experimenting with new forms of payment incentives.

FDA Approves Ramucirumab for NSCLC

December 12th 2014

The FDA has approved the VEGFR-2 inhibitor ramucirumab (Cyramza) in combination with docetaxel for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumor has progressed during or following treatment with platinum-based chemotherapy.

FDA Approves Ruxolitinib for Polycythemia Vera

December 4th 2014

The FDA has approved the JAK1/2 inhibitor ruxolitinib as treatment for patients with polycythemia vera who are resistant or intolerant to hydroxyurea

FDA Approves Blinatumomab for Acute Lymphoblastic Leukemia

December 3rd 2014

The FDA has approved the bispecific T cell engager antibody blinatumomab as a treatment for adult patients with Philadelphia chromosome-negative relapsed/refractory B-precursor acute lymphoblastic leukemia.

The Emerging "N-of-1" Model:Clinical Relevance of Individualized Tumor Profiling Grows in Research Programs

November 28th 2014

Molecular studies are increasingly utilized to develop an individual therapeutic approach based on abnormalities present in the setting of uncommon/rare cancers or in specific clinical situations where it is virtually certain that formal regulatory-based trials will never be undertaken.

Becoming a Champion of Change: Educating Fellows on the Costs of Cancer Care

November 27th 2014

On a recent day in hematology clinic, I stood dutifully by my attending as he sorted through bone marrow slides

Clinical Oncology in the 21st Century: Reflections on how Healthcare Providers Should Manage Their Public Personas on Social Media

November 23rd 2014

It is important that clinicians engage with social media, since reputations are at risk by not knowing what is being said, shared, and discussed online about them online.

Could Healthcare Reform Speed Molecular Medicine Adoption?

November 21st 2014

Over the past decade drug development in cancer has shifted to an increasingly gene target–based approach.

FDA Approves Bevacizumab for Recurrent Ovarian Cancer

November 14th 2014

The FDA has approved bevacizumab in combination with chemotherapy for patients with recurrent platinum-resistant ovarian cancer.

ASCO to Establish New Practice Management Department

November 14th 2014

ASCO members who need hands-on assistance in practice management, quality care assessment and improvement, and efficiency and business intelligence will be able to contact a soon to be established clinical affairs department at the organization.

Latest News & Insight: November 13, 2014

November 13th 2014

The Invisible Revolution

November 11th 2014

How CTCs and Circulating Naked Tumor DNA-as Liquid Biopsies-Will Transform Diagnostic and Management of Oncology Patients

Should Physicians Friend or Unfriend Social Media? 'It's Complicated'

November 11th 2014

Compared to other industries, the medical profession has been late in recognizing the many benefits of social media. In the past few years, it has entered into an uneasy relationship with the new medium.

Side Effect Management With Regorafenib in mCRC

November 8th 2014

Second- and Third-Line Therapies in mCRC

November 8th 2014

Goals of Therapy in Metastatic CRC

November 8th 2014

Selecting First-line Treatment in mCRC

November 8th 2014

Latest News & Insight: November 7, 2014

November 8th 2014

CMS Earmarks $840 Million to Encourage Practice Transformation Networks

November 7th 2014

To help clinicians rethink and redesign their practices by moving from a model that is driven by quantity of care to one focused on patients' health outcomes, the Centers for Medicare & Medicaid Services (CMS) will earmark $840 million to improve health outcomes and reduce unnecessary hospitalization and other overutilization of services.

ODAC Votes Against Panobinostat in Multiple Myeloma

November 6th 2014

In what was described as a very difficult decision, ODAC voted 5-2 against the accelerated approval of the HDAC inhibitor panobinostat in combination with bortezomib and dexamethasone as a treatment for patients with multiple myeloma who have received at least one prior therapy.